Biomarker Analysis Services for Influenza
Ace Therapeutics offers specialized biomarker analysis services tailored to support influenza research and drug discovery through preclinical development stages. Our comprehensive biomarker panel enables in-depth exploration of disease pathophysiology, providing valuable insights for the advancement of novel therapeutics. Please note that all services are exclusively focused on research applications in drug discovery and preclinical development and do not include clinical diagnostic services.
Effective therapeutic intervention for influenza begins with the discovery and identification of relevant biomarkers. At Ace Therapeutics, our biomarker discovery services are designed to elucidate molecular and cellular signatures associated with influenza pathogenesis. We employ systematic screening and validation processes, integrating high-throughput data generation with robust bioinformatics, to identify and prioritize candidate biomarkers that inform drug development strategies. Our approach encompasses initial in silico analysis, experimental screening, and rigorous validation to ensure relevance to influenza biology.
Multi Omics: Our multi-omics approach leverages cutting-edge technologies spanning genomics, transcriptomics, proteomics, and metabolomics to achieve a comprehensive understanding of biological systems perturbed during influenza infection. We analyze DNA, RNA, protein, and metabolite profiles to identify molecular signatures and pathways associated with disease progression and therapeutic response. This integrated analysis enables the identification of biomarkers linked to innate and adaptive immune responses, inflammatory cascades, and host-pathogen interactions central to influenza pathophysiology.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves a multi-tiered strategy, including experimental confirmation of expression, functional association with influenza pathophysiology, and preliminary screening in relevant preclinical models. We assess candidates based on biological plausibility, reproducibility, and their ability to reflect disease-relevant processes such as immune activation, cytokine response, and viral recognition. Promising candidates are prioritized through a combination of statistical analysis, pathway mapping, and functional assays.
Diverse Technological Platforms: Ace Therapeutics offers custom assay development utilizing a diverse array of technological platforms. Our capabilities include adaptation and optimization of assays for specific research requirements, ensuring sensitivity, specificity, and compatibility with sample types relevant to influenza studies. Platforms include immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced imaging modalities.
Immunoassays: We develop and implement ELISA, chemiluminescent, and multiplex immunoassays for the quantitative and qualitative detection of cytokines, immune checkpoint molecules, and complement components.
Mass Spectrometry: Our LC-MS/MS platforms enable high-resolution, quantitative proteomic and metabolomic analysis for the identification and quantification of protein and peptide biomarkers.
Flow Cytometry: We utilize flow cytometry for multiparametric analysis of cell surface and intracellular markers, enabling detailed immune cell profiling and functional studies.
Molecular Diagnostics: Our molecular diagnostics capabilities include quantitative PCR, digital PCR, and nucleic acid amplification for the detection and quantification of gene expression and viral RNA.
Histopathology And Imaging: We offer immunohistochemistry, in situ hybridization, and advanced imaging techniques to localize and quantify biomarker expression within tissue samples.
Rigorous Method Validation: All analytical methods undergo rigorous validation according to established research guidelines. We evaluate performance characteristics such as sensitivity, specificity, linearity, accuracy, precision, and reproducibility. Comprehensive quality control measures, including the use of reference standards, controls, and inter-assay comparisons, are implemented to ensure data integrity and reliability.
Our quantitative analysis capabilities support robust, reproducible measurement of biomarker levels across a variety of sample types. We employ validated protocols and calibrated instrumentation to ensure high data quality, supporting both exploratory and hypothesis-driven research objectives.
Sample Analysis: Ace Therapeutics handles a wide range of sample types, including blood, plasma, serum, tissue lysates, and cell culture supernatants. Our analysis protocols are optimized for sample preservation, minimal handling, and compatibility with downstream applications. Stringent quality measures, such as sample tracking, contamination control, and standardized processing, are integral to our workflow.
High Throughput Capabilities: Our high-throughput analytical platforms enable multiplexed analysis of multiple biomarkers simultaneously, increasing efficiency and conserving valuable samples. Automated liquid handling and data acquisition systems facilitate large-scale studies, accelerating the pace of biomarker discovery and validation while minimizing sample volume requirements.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| CD274 molecule (CD274) | CD274, also known as programmed death-ligand 1 (PD-L1), is a type I transmembrane protein that belongs to the B7 family of immune regulatory molecules. It is primarily expressed on antigen-presenting cells such as dendritic cells and macrophages, as well as on various non-hematopoietic cells and some tumor cells. CD274 functions as an immune checkpoint by binding to its receptor, programmed cell death protein 1 (PD-1), on T cells. This interaction transmits an inhibitory signal that reduces T cell proliferation, cytokine production, and cytolytic activity, thereby contributing to the maintenance of peripheral tolerance and prevention of autoimmunity. In the tumor microenvironment, upregulation of CD274 can facilitate immune evasion by inhibiting anti-tumor T cell responses. | CD274 (PD-L1) expression is used as a biomarker in oncology, particularly to assess the tumor microenvironment and guide immunotherapy decisions. Immunohistochemical detection of CD274 on tumor cells or infiltrating immune cells is employed to aid in identifying patients who may benefit from immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway. CD274 expression levels have been utilized in clinical practice as a companion diagnostic in several cancers, including non-small cell lung cancer, urothelial carcinoma, and others, to inform therapeutic strategies involving PD-1 or PD-L1 inhibitors. |
| CD80 molecule (CD80) | CD80, also known as B7-1, is a transmembrane protein expressed primarily on antigen-presenting cells such as dendritic cells, macrophages, and activated B cells. It plays a crucial role in the regulation of T cell-mediated immune responses. CD80 provides a co-stimulatory signal necessary for T cell activation and survival by binding to CD28 on T cells, which promotes T cell proliferation and cytokine production. Additionally, CD80 can interact with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), delivering an inhibitory signal that downregulates T cell responses. Through these interactions, CD80 is involved in maintaining immune system balance and preventing inappropriate immune activation. | CD80 expression has been used as a biomarker for the activation status of antigen-presenting cells and the assessment of immune responses. Its presence is evaluated in contexts such as autoimmune diseases, infectious diseases, and cancer, where changes in CD80 expression can reflect immune activation or suppression. In oncology, CD80 expression in tumor tissues or immune cells within the tumor microenvironment has been studied in relation to tumor immunogenicity and response to immunotherapies. Additionally, CD80 is monitored in transplantation to assess the risk of graft rejection or tolerance. |
| F2R like trypsin receptor 1 (F2RL1) | F2R like trypsin receptor 1 (F2RL1), also known as protease-activated receptor 2 (PAR2), is a member of the G protein-coupled receptor (GPCR) family. It is activated by serine proteases such as trypsin and tryptase, which cleave its extracellular N-terminus to reveal a tethered ligand that activates the receptor. Upon activation, F2RL1 initiates intracellular signaling cascades involving G proteins and beta-arrestins, leading to diverse cellular responses. F2RL1 is expressed in various tissues, including epithelial cells, endothelial cells, immune cells, and neurons. Its biological functions include regulation of inflammatory responses, modulation of pain perception, influence on vascular tone, and participation in tissue repair and remodeling. | F2RL1 has been studied as a biomarker in several pathological contexts, particularly those involving inflammation and tissue injury. Elevated expression or activation of F2RL1 has been observed in conditions such as inflammatory bowel disease, certain cancers, and chronic inflammatory disorders. Its presence or upregulation in tissue samples, blood, or other biological fluids has been associated with disease activity, severity, or progression in these contexts. Research has explored its potential utility in indicating inflammatory status, tumor microenvironment activity, or response to therapeutic interventions. |
| RNA sensor RIG-I (RIGI) | RIG-I (Retinoic acid-Inducible Gene I), encoded by the DDX58 gene, is a cytosolic pattern recognition receptor that plays a critical role in the innate immune response to viral infection. RIG-I detects viral double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA) bearing 5'-triphosphate groups, which are molecular patterns associated with many RNA viruses. Upon recognition of these RNA motifs, RIG-I undergoes conformational changes and interacts with the mitochondrial antiviral signaling protein (MAVS), leading to the activation of downstream signaling pathways. This results in the production of type I interferons and other pro-inflammatory cytokines, which are essential for establishing an antiviral state and coordinating adaptive immune responses. | RIG-I expression and activation status have been investigated as biomarkers in several contexts. Increased levels of RIG-I mRNA or protein have been observed in response to viral infections, such as influenza and hepatitis C, reflecting activation of the innate immune response. In oncology, altered RIG-I expression has been reported in certain cancers, where its presence may be associated with immune activity within the tumor microenvironment. Additionally, RIG-I has been studied as a potential biomarker for disease activity or response to therapy in autoimmune diseases and chronic viral infections. These applications are based on the measurement of RIG-I expression or pathway activation in tissues or peripheral blood. |
| complement C3 (C3) | Complement C3 (C3) is a central component of the complement system, which is a key part of the innate immune response. C3 is synthesized primarily in the liver and circulates in the blood as an inactive precursor. Upon activation by one of the three complement pathways (classical, lectin, or alternative), C3 is cleaved into C3a and C3b. C3b acts as an opsonin, binding to pathogens and facilitating their phagocytosis, while C3a functions as an anaphylatoxin, promoting inflammation by stimulating mast cells and attracting immune cells. C3 also participates in the formation of the membrane attack complex, contributing to the lysis of target cells. Through these mechanisms, C3 plays a crucial role in host defense, clearance of immune complexes, and modulation of adaptive immune responses. | Complement C3 levels are measured in clinical settings to assess the activity of the complement system. Altered C3 concentrations can reflect immune system activation or dysfunction. Decreased C3 levels are observed in conditions associated with increased complement consumption, such as systemic lupus erythematosus, certain types of glomerulonephritis, and other autoimmune or inflammatory diseases. Elevated C3 levels may be seen in acute-phase responses or metabolic disorders. Thus, C3 serves as a biomarker for monitoring disease activity, aiding in diagnosis, and evaluating treatment response in various immune-mediated and inflammatory conditions. |
| interferon gamma (IFNG) | Interferon gamma (IFNG) is a cytokine produced primarily by activated T lymphocytes and natural killer (NK) cells. It plays a central role in innate and adaptive immunity by promoting the activation of macrophages, enhancing antigen presentation through upregulation of major histocompatibility complex (MHC) molecules, and stimulating the differentiation of T helper 1 (Th1) cells. IFNG is also involved in the regulation of immune responses to intracellular pathogens, such as viruses and certain bacteria, and contributes to the modulation of cell proliferation, apoptosis, and immune surveillance. | IFNG is measured in various clinical and research settings as an indicator of cell-mediated immune activity. Its expression or secretion is commonly assessed in assays evaluating immune responses to infections, such as tuberculosis, where IFNG release assays (IGRAs) are used to detect latent or active infection. Additionally, IFNG levels are monitored in studies of autoimmune diseases, transplant rejection, and immunotherapy responses, reflecting the degree of Th1-type immune activation. |
| lymphocyte antigen 96 (LY96) | Lymphocyte antigen 96 (LY96), also known as MD-2, is a secreted protein that plays a critical role in the innate immune response. LY96 forms a complex with Toll-like receptor 4 (TLR4) on the cell surface, which is essential for the recognition of bacterial lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria. Upon binding to LPS, the LY96-TLR4 complex initiates downstream signaling pathways that activate nuclear factor-kappa B (NF-κB) and other transcription factors, leading to the production of pro-inflammatory cytokines. This process is central to the detection of bacterial infection and the initiation of the inflammatory response. | LY96 expression and protein levels have been studied in the context of inflammatory conditions and infectious diseases. Alterations in LY96 levels have been reported in sepsis, systemic inflammatory response syndrome, and certain autoimmune disorders. Measurement of LY96, alone or in combination with other markers, has been explored for its potential to reflect activation of the innate immune response and to provide information on disease presence or progression in these settings. |
| serpin family G member 1 (SERPING1) | Serpin family G member 1 (SERPING1), also known as C1 esterase inhibitor (C1-INH), is a serine protease inhibitor that plays a key role in regulating the complement system, particularly the classical and lectin pathways. It inhibits the proteases C1r and C1s of the C1 complex, as well as MASP-1 and MASP-2 of the lectin pathway, thereby controlling complement activation and preventing spontaneous or excessive inflammation. Additionally, SERPING1 regulates other protease systems, including the contact, coagulation, and fibrinolytic pathways, by inhibiting plasma kallikrein and factor XIIa. Deficiency or dysfunction of SERPING1 leads to uncontrolled activation of these pathways, resulting in increased vascular permeability and angioedema. | SERPING1 levels and activity are commonly measured in the evaluation of hereditary angioedema (HAE), a disorder characterized by recurrent episodes of angioedema due to SERPING1 deficiency or dysfunction. Quantification of SERPING1 protein and assessment of its functional activity assist in the differential diagnosis of HAE types I and II, and distinguish them from acquired forms of angioedema. In clinical practice, SERPING1 measurement aids in the identification of patients at risk for angioedema attacks and guides therapeutic management. |
| toll like receptor 4 (TLR4) | Toll-like receptor 4 (TLR4) is a transmembrane protein that plays a central role in the innate immune system. It functions as a pattern recognition receptor (PRR), primarily recognizing lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria. Upon ligand binding, TLR4 initiates intracellular signaling cascades that activate transcription factors such as NF-κB and interferon regulatory factors, leading to the production of pro-inflammatory cytokines and type I interferons. This response is critical for the early detection of pathogens and the initiation of host defense mechanisms. TLR4 is expressed on various immune cells, including macrophages, dendritic cells, and neutrophils, as well as some non-immune cell types. | TLR4 expression and activity have been investigated as biomarkers in several contexts involving inflammation and immune responses. Elevated TLR4 levels or signaling activity have been observed in infectious diseases, sepsis, and certain chronic inflammatory conditions, such as atherosclerosis and autoimmune disorders. In cancer research, TLR4 has been studied for its association with tumor progression and response to therapy. Quantification of TLR4 expression in tissues or blood samples has been used in research settings to assess disease states or monitor responses to treatment, particularly in studies of inflammatory and infectious diseases. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as by other cell types such as lymphocytes, natural killer cells, and endothelial cells. TNF plays a central role in the regulation of immune responses, inflammation, cell proliferation, differentiation, and apoptosis. It mediates its effects through binding to two distinct receptors, TNFR1 and TNFR2, activating downstream signaling pathways including NF-κB and MAPK. TNF is involved in host defense against infections and is a key mediator in the pathogenesis of various inflammatory and autoimmune diseases. | TNF is utilized as a biomarker to assess inflammation and immune activation in various clinical contexts. Elevated TNF levels have been associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. Measurement of circulating TNF concentrations can provide information on disease activity, severity, and response to anti-TNF therapies in some inflammatory disorders. |
Explore Research Opportunities with Ace Therapeutics. Our comprehensive biomarker research services are designed to advance understanding of influenza pathophysiology and support drug discovery efforts through preclinical development. We offer a full suite of exploratory analytical capabilities, from biomarker discovery and multi-omics profiling to assay development and quantitative analysis. Please note that all biomarkers discussed are research targets only; we do not claim any as validated or mandatory for influenza studies. Our services are focused exclusively on preclinical research, and we maintain strict scientific objectivity in all collaborative projects.
We invite you to connect with Ace Therapeutics to discuss collaborative opportunities in exploratory biomarker research for influenza. Our team is dedicated to advancing scientific knowledge through objective, preclinical investigations. Let’s work together to drive innovation in influenza therapeutic development.
Make Order
Experimental Scheme
Implementation
Conclusion
